Introduction:The endemicity of rubella has been well established in India and immunity to rubella in pregnant women can indirectly hint at the risk of acquiring Congenital Rubella Syndrome CRS. In India Rubella vaccine has not been introduced in universal immunization program (UIP) at national level and has been used in only in private sectors which cover only a small proportion of population. In the state no community based studies were conducted among pregnant women to study the immunity against rubella which will reflect their vulnerability to future infection. Aims: The present study was carried out primarily to assess the IgG seroprevalence of rubella in pregnant women. Second, to identify potential predictors of rubella immunity like age, gravidity and previous abortions. Material methods: The study was conducted in Mavoor panchayath area of Kozhikode district, Kerala. The subjects were pregnant women (n=70) of any period of gestation who were permanent residents of the area were selected by systematic random sampling from antenatal register. The data collection, blood sample collection and estimation of Rubella specific I G antibody was done by enzyme linked immunesorbent assay (ELIZA) method. Results: The mean age was 24.7 ± (SD4.3) years. The mean titre value was 192.45 ± 102.58 IU and 94.3% (95%CI 86.2 -97.8) were Ig G positive .There was no difference between IgG levels among different trimesters, age or gravidity. Among those with history of abortion 100% and those without history of abortion 96.4% were Ig G positive. Conclusion: This study indicates that rubella is still an endemic condition in India, majority of pregnant women have acquired immunity towards rubella. More detailed epidemiological studies by taking samples from different states may be needed for a basis of national immunization program.
Context:Rubella is a mild self-limiting disease all over the world; nevertheless, it is of significant public health importance due to its teratogenic effect of congenital rubella syndrome. Rubella vaccine is currently not included in the national immunization program in India. Rubella-specific IgG in the unvaccinated population is a marker of previous rubella infection. Rubella IgG estimation in children will provide data for initiation and necessary modification to the immunization strategy.Aims:In this background, this study was conducted with an aim to know the age-specific susceptibility of acquiring rubella infections and future risk of congenital rubella syndrome (CRS) among girls.Settings and Design:This was a community-based, observational study.Participants and Methods:The study was conducted at a randomly selected rural area Mavoor Panchayath of Kozhikode District, Kerala, among adolescent girls. The estimation of rubella-specific IgG antibody was done by quantitative enzyme-linked immunosorbent assay method. IgG titer value of >15 IU was taken positive, 8–15 IU as equivocal, and <8 IU as negative.Statistical Analysis Used:Statistical analysis was performed using Statistical program for Social science version 16 for Windows. Chi-square test was applied to find out significant difference and Fisher's exact test wherever applicable.Results:The data and blood sample collection was done from 250 girls. The mean IgG titer was 151.93 ± 128.78 IU, and as per the criteria, 68.3% were positive, 28.5% were negative, and 3.2% were equivocal. At this age, majority (68.3%) of the girls get protection by natural infection without any vaccine. Some girls (32%) may remain susceptible to infection during adulthood and pregnancy.Conclusions:Natural rubella infection was widely prevalent among child population and at this age. An immunization policy recommending rubella-containing vaccine is highly desirable to prevent rubella and CRS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.